Estimating The Fair Value Of Hikma Pharmaceuticals PLC (LON:HIK)

Does the share price for Hikma Pharmaceuticals PLC (LON:HIK) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by taking the foreast future cash flows of the company and discounting them back to today’s value. I will use the discounted cash flows (DCF) model. It may sound complicated, but actually it is quite simple! Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. Please also note that this article was written in August 2018 so be sure check out the updated calculation by following the link below.

Check out our latest analysis for Hikma Pharmaceuticals

What’s the value?

I’m using the 2-stage growth model, which simply means we take in account two stages of company’s growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have perpetual stable growth rate. In the first stage we need to estimate the cash flows to the business over the next five years. For this I used the consensus of the analysts covering the stock, as you can see below. The sum of these cash flows is then discounted to today’s value.

5-year cash flow estimate

2018 2019 2020 2021 2022
Levered FCF ($, Millions) $275.93 $234.67 $280.07 $347.00 $383.41
Source Analyst x6 Analyst x6 Analyst x3 Analyst x1 Est @ 10.49%
Present Value Discounted @ 8.28% $254.83 $200.15 $220.61 $252.43 $257.59

Present Value of 5-year Cash Flow (PVCF)= US$1.19b

The second stage is also known as Terminal Value, this is the business’s cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of the GDP. In this case I have used the 10-year government bond rate (1.4%). In the same way as with the 5-year ‘growth’ period, we discount this to today’s value at a cost of equity of 8.3%.

Terminal Value (TV) = FCF2022 × (1 + g) ÷ (r – g) = US$383.41m × (1 + 1.4%) ÷ (8.3% – 1.4%) = US$5.65b

Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = US$5.65b ÷ ( 1 + 8.3%)5 = US$3.80b

The total value, or equity value, is then the sum of the present value of the cash flows, which in this case is US$4.98b. In the final step we divide the equity value by the number of shares outstanding. If the stock is an depositary receipt (represents a specified number of shares in a foreign corporation) or ADR then we use the equivalent number. This results in an intrinsic value in the company’s reported currency of $20.63. However, HIK’s primary listing is in United Kingdom, and 1 share of HIK in USD represents 0.785 ( USD/ GBP) share of LSE:HIK, so the intrinsic value per share in GBP is £16.19. Relative to the current share price of £17.45, the stock is fair value, maybe slightly overvalued at the time of writing.

LSE:HIK Intrinsic Value Export August 16th 18
LSE:HIK Intrinsic Value Export August 16th 18

Important assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. You don’t have to agree with my inputs, I recommend redoing the calculations yourself and playing with them. Because we are looking at Hikma Pharmaceuticals as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighed average cost of capital, WACC) which accounts for debt. In this calculation I’ve used 8.3%, which is based on a levered beta of 0.800. This is derived from the Bottom-Up Beta method based on comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn’t be the only metric you look at when researching a company. For HIK, I’ve compiled three fundamental factors you should further examine:

  1. Financial Health: Does HIK have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Future Earnings: How does HIK’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of HIK? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St does a DCF calculation for every GB stock every 6 hours, so if you want to find the intrinsic value of any other stock just search here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.